Developing affordable, next-generation biopharmaceuticals for animal health

Raising the standard of veterinary care

Pets are living longer, and that calls for a new standard of care.

Fortgen Biologics was founded with the purpose of transforming the treatment of diseases and chronic conditions in animals, such as cancer, pain, and allergies, by bringing the most advanced innovations in global biotechnology.

Our commitment is to radically elevate the standard of animal health by combining scientific innovation, efficacy, and economic viability in the production of biopharmaceuticals.

The untapped use of biopharmaceuticals for animal health

While human medicine already makes extensive use of biopharmaceuticals, veterinary medicine still faces technological and economic barriers that limit access to these therapies. The main challenge lies in the high cost of developing and producing these complex molecules on conventional platforms, given the lower price ceiling of the veterinary market. Fortgen was created to break this paradigm, making biopharmaceuticals for animal health accessible without compromising safety or therapeutic performance.

Innovation and technological expertise that can revolutionize

Fortgen Biologics has mastered technologies that enable the efficient, scalable production of highly complex biopharmaceuticals, with a focus on monoclonal antibodies (mAbs).

Our key technologies:

Phage display: a powerful technology for the discovery and selection of high-affinity, highly specific monoclonal antibodies.
Animal Platform: a recombinant protein expression system in milk that reduces costs while maintaining therapeutic performance.
Smart manufacturing processes: designed for industrial scalability and low production costs.

We are democratizing access to biological therapies that were once exclusive to human medicine.

Technology that generates potent and affordable biopharmaceuticals

Our technology platform integrates complementary solutions that increase efficiency and reduce costs.

Core components:

Phage Display: discovery and selection of highly specific, effective antibodies.
Animal Platform: large-scale production with cost efficiency and sustainability.

The result is powerful, safe, and economically viable biopharmaceuticals for animal health, representing a major leap forward in innovation for animal health.

A strategic partner for biopharmaceutical production

Fortgen Biologics acts as both a leader and a strategic partner in advancing the production of biopharmaceuticals for animal health. In addition to developing our own portfolio of monoclonal antibodies, we are open to co-development partnerships, licensing, and collaborative R&D projects.

Our goal is to create value by driving a new era of accessible and sustainable innovation in animal health.

Partnerships and Technological Collaboration

Pipeline Co-Development and Licensing

We offer opportunities for licensing and engagement in the co-development of monoclonal antibodies already in development, allowing partners to benefit from our technological advances and R&D efforts.

Collaborative Biopharmaceutical Discovery

We work alongside you to develop new biopharmaceuticals,
leveraging our expertise and technology.

Serviços de Upstream:

One of the greatest strengths of the technological platform we use lies in the cost efficiency and scalability
of upstream processes. This is critical to achieving industrial viability in the production of biopharmaceuticals for animal health.